Navigation Links
Private-label OTC Drugs Post Solid Gains in 2008, According to Kline

LITTLE FALLS, N.J., April 8 /PRNewswire/ -- Manufacturers' sales of OTC drugs grew by 2.4% from $17.8 million in 2007 to $18.3 million in 2008, according to the latest research in Nonprescription Drugs USA 2008: Market Analysis and Opportunities from worldwide consulting and research firm Kline & Company.

Private-label OTC medicines were up 8.2% over the same time period, within which antacids and allergy medicines posted the highest growth last year, driven primarily by increases in sales of private-label omeprazole (Procter & Gamble's Prilosec OTC) and cetirizine (Johnson & Johnson's Zyrtec).

The following two areas distinctively posted very high growth mainly as a result of Rx-to-OTC switches: allergy, asthma, and sinus medications were up 17.3% as a result of strong sales from Johnson & Johnson's Zyrtec brand, as well as its equivalent private-label cetirizine; feminine products was the other area that grew 7.3% in 2008 as a result of strong sales growth of personal lubricants, as well as the Rx-to-OTC switch brand Plan B by Barr Laboratories.

"By contrasting the overall growth rates for OTCs with the growth rates for private-label products we can easily make the case that more Americans were seeking value and using private-label in 2008," says Laura Mahecha, industry manager at Kline's Healthcare practice. However, not all categories suffer from higher private-label growth as some are able to maintain growth for branded products. "During tough economic times, consumers are willing to spend more for some brands they are loyal to and that offer good efficacy," says Mahecha. However, if consumers view brands as being a commodity or not offering special advantages they may be able to make the trade-off to private-label. Mahecha goes on to say, "As the recession continues into 2009, we expect to see increased 'value messages' as part of branded advertising to combat the impacts of private-label erosion. Branded OTCs may use advertising messages to stress the brand's value, efficacy, safety, and possibly longer-lasting doses, which translates into fewer doses and therefore, costs less."

According to preliminary research for Kline's upcoming report Impact of Recessions on the U.S. OTC Market, past declines during recessions have not been particularly steep for the industry. OTC sales declined two years in a row; from 1999 to 2000 overall manufacturers' sales were down 0.6%, and then it declined again from 2000 to 2001 by 0.5%. Declines for the market were kept at bay possibly as a result of Rx-to-OTC switches, continued innovation, and to some extent sustained private-label sales, albeit at lower price points. There may also have been some spill over from Rx patients who chose OTCs as less expensive alternative in some cases to Rx medications and MD visits. Further research for this study will analyze the shifts in ad spending by marketers, shifts in private-label share, and the impacts innovations have had on industry performance during past recessions in order to forecast impacts of the current recession.

Kline's Nonprescription Drugs 2008: U.S. Market Analysis and Opportunities contains sales data on hundreds of OTC brands and companies, new product and ad spending analysis, retail distribution, five years historical sales and five year sales forecasts for 36 major product categories, detailed profiles of 15 leading marketers and 50 minor companies, and an analysis of media spending.

Kline's Impact of Recessions on the U.S. OTC Market is a comprehensive assessment that will provide subscribers with a historical perspective on industry performance during recessions over the past three decades and forecasts impacts of the current economic recession on OTC sales performance.

About Kline

Kline is a worldwide consulting and research firm dedicated to providing the kind of insight and knowledge that helps companies find a clear path to success. The firm has served the management consulting and market research needs of organizations in the chemicals, materials, energy, life sciences, and consumer products industries for 50 years. For more information, visit

    For more information, contact:
    Vera Sandarova
    Marketing Communications

SOURCE Kline & Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Canadian Brand-Name Infant Formulas No Better than Private-Label Formulas
2. Certain Diabetes Drugs May Pose Eye Risk
3. Breakthrough model for human cancer may improve development of cancer drugs; study in PNAS
4. More U.S. Kids Taking Diabetes, Blood Pressure Drugs
5. Link between widely used osteoporosis drugs and heart problems probed
6. Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
7. Researchers question effectiveness of warning labels on over-the-counter drugs
8. Patients Say MPM Medicals Regenecare Gel Significantly Reduced the Itching and Pain of Skin Rashes Triggered by Anti-Cancer Drugs
9. IROs Help Decide Medically on Approved Uses of Off-Label Drugs for Cancer
10. Dogs Help in Hunt for New Cancer Drugs
11. Study finds most adolescents sent to group homes still involved with drugs/crime seven years later
Post Your Comments:
(Date:11/28/2015)... PITTSBURGH, PA (PRWEB) , ... November 28, 2015 , ... ... Manalapan, N.J., has created the COUCH BUDDY. "I conceived of this design due to ... more comfort for couch users. It promotes relaxation and convenience, as well as increases ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of ... in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately ... nationally, through a vast social media strategy and across a network of top ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
Breaking Medicine Technology: